Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

Study finds racial and ethnic disparities in the use of obesity-management drugs

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to lower their weight compared with whites, new research suggests.

18 Dec 2024

Nutraceuticals: exploring potential benefits and challenges of an unregulated healthcare frontier

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues must be addressed for effective use.

18 Dec 2024

Danish studies find increased risk of optic nerve damage with diabetes medicine

Two independent studies from the University of Southern Denmark (SDU) show that patients with type 2 diabetes who are treated with the drug Ozempic have an increased risk of developing damage to the optic nerve of the eye, which can lead to severe and permanent loss of vision.

16 Dec 2024

Obesity prevalence and BMI decrease in the US for the first time in a decade

Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.

16 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

The brain’s hunger switch: TRH neurons hold the key to obesity therapies

Scientists uncover how TRH neurons suppress hunger by inhibiting AgRP neurons, advancing our understanding of GLP-1-based obesity treatments.

9 Dec 2024

A reduction in BMI among adults is associated with lower health care spending, study suggests

A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% for a 25% reduction in adults.

6 Dec 2024

Anti-obesity medications could help treat alcohol use disorders

Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open.

4 Dec 2024

MIT engineers develop inflatable gastric balloon for weight loss

Gastric balloons -; silicone balloons filled with air or saline and placed in the stomach -; can help people lose weight by making them feel too full to overeat.

3 Dec 2024

Who gets obesity drugs covered by insurance? In North Carolina, it helps if you’re on Medicaid

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets don't work.

2 Dec 2024

Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication

Researchers evaluate changes in alcohol use after initiating antiobesity medication.

29 Nov 2024

Expert explores the expanding applications of GLP1 therapies

Researchers review recent advancements in glucagon-like peptide-1-based therapies.

28 Nov 2024

Can fasting improve diabetes outcomes? Ramadan offers insights

A study during Ramadan shows intermittent fasting improves liver health, gut microbiota richness, and metabolic markers in T2DM patients. However, benefits fade quickly after fasting ends, highlighting the need for sustained interventions.

27 Nov 2024

GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

27 Nov 2024

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

26 Nov 2024

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.

25 Nov 2024

How neural and hormonal gut-brain communication shapes metabolism and health

Interoception research reveals how gut-brain communication via neural, hormonal, and microbial pathways regulates metabolism, hunger, and overall health, offering insights for therapeutic innovations.

25 Nov 2024

New oral peptide therapy offers hope for chronic abdominal pain

A research team at the University of Vienna, led by medicinal chemist Markus Muttenthaler, has developed a new class of oral peptide therapeutic leads for treating chronic abdominal pain.

22 Nov 2024

Anti-obesity drugs increase food waste in some users

Taking anti-obesity drugs has led some U.S. adults to throw away more food than they tossed before starting the medications, a new study has found.

22 Nov 2024

Ingestible capsule releases a burst of drugs directly into the walls of the GI tract

Inspired by the way that squids use jets to propel themselves through the ocean and shoot ink clouds, researchers from MIT and Novo Nordisk have developed an ingestible capsule that releases a burst of drugs directly into the wall of the stomach or other organs of the digestive tract.

21 Nov 2024